Healthcare Global Enterprises has updated its investor presentation for Q3 and nine months ended December 31, 2025, incorporating certain clarifications and corrections. The company filed the updated presentation with stock exchanges on February 6, 2026, superseding the earlier version submitted on February 5, 2026.

Regulatory Filing Details

The updated investor presentation was filed under Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company requested that the earlier presentation be treated as withdrawn and superseded by the updated version.

Company Performance Highlights

The updated presentation covers Healthcare Global Enterprises' financial results for the quarter and nine months ended December 31, 2025. The company operates as India's largest pan-India oncology-focused hospital chain with presence across 19 cities and 10 states, maintaining 25 hospitals with over 2,500 capacity beds.

Leadership and Authorization

The updated filing was digitally signed and authorized by Sunu Manuel, Company Secretary and Compliance Officer, on February 6, 2026. The company maintains its registered office at HCG Towers, Sampangi Ram Nagar, Bengaluru, and corporate office at Unity Buildings Complex, Mission Road, Bengaluru.

Network Presence

Healthcare Global Enterprises operates across multiple locations including Ahmedabad, Bengaluru, Bhavnagar, Chennai, Cuttack, Hubballi, Indore, Jaipur, Kalaburagi, Kenya, Kolkata, Mumbai, Nagpur, Nashik, Ongole, Rajkot, Ranchi, Shimoga, Vadodara, Vijayawada, and Vizag, establishing itself as a comprehensive cancer care provider.

Healthcare Global Enterprises Limited's Board of Directors has approved the introduction and adoption of a new employee stock option scheme during their meeting held on February 05, 2026. The HCG Employee Stock Option Scheme 2026 (HCG ESOS 2026) was approved based on recommendations from the company's Nomination and Remuneration Committee.

ESOP Scheme Details

The newly approved employee stock option scheme encompasses significant parameters for employee benefits:

Vesting and Exercise Framework

The scheme will be administered by the Nomination and Remuneration Committee, with specific guidelines for vesting periods:

• Minimum vesting period: 1 year from grant date
• Maximum vesting period: 7 years from grant date
• Exercise timeline: As per ESOP scheme terms
• Committee oversight: NRC will determine specific vesting schedules

Pricing Structure

The exercise price structure follows a tiered approach based on grant timing. For options granted prior to June 30, 2026, the exercise price is fixed at INR 495. For options granted after June 30, 2026, the Nomination and Remuneration Committee will determine the price, ensuring it remains not below INR 495.

Regulatory Compliance and Approval Process

The HCG ESOS 2026 aligns with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The board meeting, which commenced at 12 noon and concluded at 7.35 p.m. IST, addressed the regulatory requirements under Regulation 30 of SEBI Listing Regulations.

Key compliance aspects:

• Subject to shareholders' approval
• Detailed explanatory statement for shareholders' meeting
• Full regulatory disclosure requirements met
• SEBI circular compliance maintained

Current Status

As this represents a new employee stock option plan, no options have been vested, exercised, or lapsed to date. The scheme implementation awaits shareholder approval, after which the company can proceed with grant allocations to eligible employees. The board's decision reflects the company's commitment to employee retention and incentivization through equity participation.